Nov 16 (Reuters) – Drugmaker Eli Lilly has signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with Stipple Bio, the privately held biotech firm said on Monday.
Stipple Bio said it will identify cancer-specific molecules using its Pointillist discovery platform, while Lilly will use those to develop cancer therapies.
Stipple Bio will receive an upfront payment, an equity investment from Lilly, and aggregate payment up to $5.9 billion in research, development and commercial milestone payments, as well as tiered royalties on product sales if any therapies resulting from the collaboration reach the market.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

